Avantor, Inc. (NYSE:AVTR) Stock Holdings Decreased by Country Trust Bank

Country Trust Bank decreased its stake in shares of Avantor, Inc. (NYSE:AVTR) by 3.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,780,015 shares of the company’s stock after selling 59,597 shares during the period. Country Trust Bank owned about 0.26% of Avantor worth $37,505,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Norris Perne & French LLP MI raised its stake in Avantor by 1.8% during the fourth quarter. Norris Perne & French LLP MI now owns 500,662 shares of the company’s stock worth $10,549,000 after acquiring an additional 8,966 shares during the period. Forsta AP Fonden raised its position in shares of Avantor by 3.3% during the 4th quarter. Forsta AP Fonden now owns 151,800 shares of the company’s stock worth $3,198,000 after purchasing an additional 4,900 shares during the period. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Avantor by 38.1% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 119,063 shares of the company’s stock worth $2,509,000 after purchasing an additional 32,838 shares during the last quarter. CKW Financial Group boosted its position in Avantor by 116.7% during the 4th quarter. CKW Financial Group now owns 5,200 shares of the company’s stock valued at $110,000 after purchasing an additional 2,800 shares during the period. Finally, Pacer Advisors Inc. grew its stake in Avantor by 0.5% during the 4th quarter. Pacer Advisors Inc. now owns 99,825 shares of the company’s stock worth $2,103,000 after buying an additional 542 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Robert W. Baird dropped their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. UBS Group reiterated a “neutral” rating and set a $25.00 price target (down previously from $29.00) on shares of Avantor in a research report on Friday, January 17th. Raymond James lowered their price target on Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a report on Tuesday, January 21st. Wells Fargo & Company reduced their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, October 28th. Finally, Barclays lowered their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Avantor has an average rating of “Moderate Buy” and a consensus target price of $27.38.

Avantor Stock Up 3.4 %

AVTR stock opened at $22.22 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The firm has a market cap of $15.12 billion, a PE ratio of 48.29, a P/E/G ratio of 3.82 and a beta of 1.28. Avantor, Inc. has a 12 month low of $19.59 and a 12 month high of $28.00. The firm has a 50 day simple moving average of $21.66 and a 200 day simple moving average of $23.43.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.